This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Companion Diagnostics Market, 2012-2023

The Companion Diagnostics Market, 2013-2023 report provides an extensive study of the emerging market of companion diagnostics. The report differentiates personalised medicine diagnostics and companion diagnostics; we have separately defined these two closely associated markets and provided our estimates of the market size for each. The report covers various aspects, such as, advantages of personalised medicine over traditional medicine and the need for companion diagnostics.

One of the key objectives of this report is to understand the current state of the companion diagnostics market. This is done by analysing • Products currently available in the market and those under development, • Pharmaceutical and diagnostic companies active in the market, and • Deals and collaborations in the recent years

The market for companion diagnostics has also been evaluated regionally; this provides a greater clarity in the differing approaches various regions have towards personalised medicine and companion diagnostics. In parallel, we have also analysed the market for companion drugs that are associated with companion diagnostics.

The report provides market forecasts for the period 2012 - 2023. We have discussed, in detail, the key drivers behind the regional and global growth. The research, analysis and insights presented in this report include the sales of all companion diagnostic tests that are essential before prescription of any companion drug.

All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Key Highlights1. The global companion diagnostics market is likely to achieve sales of USD 897 MM by 2018, growing at a compounded annual growth rate (CAGR) of 29.2% from 2012 to 2018.2. In 2011, 41.2% of the new molecular entities (NMEs) were approved with a pharmacogenomic biomarker by the FDA.3. The sales of marketed companion drugs generated estimated revenues of more than USD 22 BN in 2012, with six drugs achieving blockbuster status.4. In terms of value, 95.9% of the sales in the companion drugs market was contributed by drugs indicated for cancer.5. The overall companion drugs market is dominated by three leading companies – Roche Laboratories, Novartis and Pfizer. Together these companies accounted for 61.3% of the companion drugs market in 2012.6. There are several personalised medicine diagnostics in the market, with companion diagnostics constituting its subset. Companion diagnostics represented 10.1% of the personalised medicine diagnostics market in 2012.7. The pipeline for companion diagnostics is rich with most products being developed with the collaborative effort of pharmaceutical and diagnostics companies. Many start-ups diagnostic companies are also engaged in partnership with large pharmaceutical companies for developing companion diagnostic tests.8. The US was the largest market for companion diagnostics in 2012, accounting for 41.0% of the total market.

1. EXECUTIVE SUMMARY1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines1.4. Key Highlights1.4.1. Oncology is the Leading Indication for Companion Drugs1.4.2. Roche is One of the Most Active Companies in the Market1.4.3. Partnership is the Preferred Model for Companion Diagnostics Development1.4.4. US is the Largest Market for Companion Diagnostics1.4.5. Opportunities Outpace the Threats

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.60%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.12 -4.00%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs